Synflorix is a polysaccharide conjugate vaccine indicated for active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae.
Synflorix is licensed for use in infants and children aged from 6 weeks to 2 years.
It offers protection against the same 7 serotypes of S. pneumoniae as Prevenar, plus three additional strains (1, 5 and 7F). These 10 serotypes are collectively thought to be responsible for 56–90% of cases of invasive pneumococcal disease in children aged under 5 years in Europe.
Further information: GSK